DrugPatentWatch Database Preview
EXFORGE HCT Drug Profile
When do Exforge Hct patents expire, and what generic alternatives are available?
Exforge Hct is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.
This drug has sixty-two patent family members in thirty-two countries.
The generic ingredient in EXFORGE HCT is amlodipine besylate; hydrochlorothiazide; valsartan. There are fifty drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the amlodipine besylate; hydrochlorothiazide; valsartan profile page.
Summary for EXFORGE HCT
International Patents: | 62 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Suppliers / Packagers: | 2 |
Clinical Trials: | 14 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for EXFORGE HCT |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for EXFORGE HCT |
DailyMed Link: | EXFORGE HCT at DailyMed |

Pharmacology for EXFORGE HCT
Drug Class | Dihydropyridine Calcium Channel Blocker Angiotensin 2 Receptor Blocker Thiazide Diuretic |
Mechanism of Action | Calcium Channel Antagonists Angiotensin 2 Receptor Antagonists |
Physiological Effect | Increased Diuresis |
US Patents and Regulatory Information for EXFORGE HCT
Expired US Patents for EXFORGE HCT
Paragraph IV (Patent) Challenges for EXFORGE HCT
Drugname | Dosage | Strength | RLD | Date |
---|---|---|---|---|
➤ Subscribe | Tablets | 10 mg/12.5 mg/160 mg | ➤ Subscribe | ➤ Try a Free Trial |
➤ Subscribe | Tablets | 5 mg/12.5 mg/160 mg, 5 mg/25 mg/160 mg, 10 mg/25 mg/160 mg and 10 mg/25 mg/320 m | ➤ Subscribe | ➤ Try a Free Trial |
International Patents for EXFORGE HCT
Country | Document Number | Estimated Expiration |
---|---|---|
Morocco | 30529 | ➤ Try a Free Trial |
European Patent Office | 1507529 | ➤ Try a Free Trial |
Chile | 2007001870 | ➤ Try a Free Trial |
Canada | 2486144 | ➤ Try a Free Trial |
Peru | 05422012 | ➤ Try a Free Trial |
Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for EXFORGE HCT
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
C0033 | France | ➤ Try a Free Trial | PRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: 6167801 20110705 |
00486 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: COMBINATIE VAN OLMESARTANMEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, AMLODIPINEBESYLAAT AND HYDROCHLOORTHIAZIDE; NATL REGISTRATION NO/DATE: RVG 106667, RVG 106671-74, RVG 106682-86 20101221; FIRST REGISTRATION: DE 79810.00.00-79814.00.00 20101216 |
0443983/03 | Switzerland | ➤ Try a Free Trial | PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009 |
C0048 | France | ➤ Try a Free Trial | PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707 |
12/018 | Ireland | ➤ Try a Free Trial | PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705 |
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |